Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
2009 2
2010 1
2011 1
2012 6
2013 3
2014 4
2015 9
2016 9
2017 3
2018 1
2019 1
2020 3
2021 3
2022 8
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.
Tang Z, Wang Y, Liu D, Wang X, Xu C, Yu Y, Cui Y, Tang C, Li Q, Sun J, Zhang Q, Ji Y, Ma G, Li H, Shen Z, Shen K, Zheng R, Hou Z, Liu T, Wang J, Sun Y. Tang Z, et al. Among authors: hou z. Nat Commun. 2022 Nov 10;13(1):6807. doi: 10.1038/s41467-022-34403-5. Nat Commun. 2022. PMID: 36357415 Free PMC article. Clinical Trial.
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
Wang T, Tang J, Yang H, Yin R, Zhang J, Zhou Q, Liu Z, Cao L, Li L, Huang Y, Jiang K, Wang W, She F, Guan N, Hou Z, Li N, Wu L. Wang T, et al. Among authors: hou z. JAMA Oncol. 2022 Aug 1;8(8):1169-1176. doi: 10.1001/jamaoncol.2022.2253. JAMA Oncol. 2022. PMID: 35771546 Free PMC article. Clinical Trial.
Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.
Lin Z, Cai M, Zhang P, Li G, Liu T, Li X, Cai K, Nie X, Wang J, Liu J, Liu H, Zhang W, Gao J, Wu C, Wang L, Fan J, Zhang L, Wang Z, Hou Z, Ma C, Yang K, Wu G, Tao K, Zhang T. Lin Z, et al. Among authors: hou z. J Immunother Cancer. 2021 Nov;9(11):e003554. doi: 10.1136/jitc-2021-003554. J Immunother Cancer. 2021. PMID: 34725214 Free PMC article. Clinical Trial.
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J, Qin S, Wen L, Wang J, Deng W, Guo W, Jia T, Jiang D, Zhang G, He Y, Ba Y, Zhong H, Wang L, Lin X, Yang J, Zhao J, Bai Y, Wu X, Gao F, Sun G, Wu Y, Ye F, Wang Q, Xie Z, Yi T, Huang Y, Yu G, Lu L, Yuan Y, Li W, Liu L, Sun Y, Sun Y, Yin L, Hou Z. Li J, et al. Among authors: hou z. BMC Med. 2023 May 5;21(1):173. doi: 10.1186/s12916-023-02841-7. BMC Med. 2023. PMID: 37147645 Free PMC article. Clinical Trial.
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
Lin Y, Qin S, Li Z, Yang H, Fu W, Li S, Chen W, Gao Z, Miao W, Xu H, Zhang Q, Zhao X, Bao J, Li L, Ren Y, Lin C, Jing S, Ma Q, Liang J, Chen G, Zhang H, Zhang Y, Zhou X, Sang Y, Hou Z. Lin Y, et al. Among authors: hou z. JAMA Oncol. 2022 Feb 1;8(2):242-250. doi: 10.1001/jamaoncol.2021.6268. JAMA Oncol. 2022. PMID: 34913959 Free PMC article. Clinical Trial.
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S, Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F. Meng X, et al. Among authors: hou z. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):245-253. doi: 10.1016/S2468-1253(21)00378-2. Epub 2022 Jan 6. Lancet Gastroenterol Hepatol. 2022. PMID: 34998471 Clinical Trial.
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X, Xu H, Chen X, Xu T, Tian Y, Wang D, Guo F, Wang K, Jin G, Li X, Wang R, Li F, Ding Y, Tang J, Fang Y, Zhao J, Liu L, Ma L, Meng L, Hou Z, Zheng R, Liu Y, Guan N, Zhang B, Tong S, Chen S, Li X, Shu Y. Chen X, et al. Among authors: hou z. Signal Transduct Target Ther. 2024 Mar 25;9(1):73. doi: 10.1038/s41392-024-01773-9. Signal Transduct Target Ther. 2024. PMID: 38528050 Free PMC article. Clinical Trial.
57 results